智慧財產權月刊 216 期

8 /104

8
本月專題
我國藥品專利保護之現況與未來——從專利連結制度之研擬談起
105.12 智慧財產權月刊 VOL.216
7 ޴༰׵Չ˼Ҧஔჯਹdᖹۜ೯׼׵ਖ਼лՓܓ ʘतࣿ׌dܼ͉̍˖˸ɨה ীሞʘਖ਼лቇࣸ׌e
ַᚃ׌ᖹۜ೯׼ʘਖ਼лڭ ᚐeᖹۜਖ਼лಂගַڗ ʿਖ਼лᛆࣖɢʔʿ׵ɪ̹Ϟᗫ޼Ӻ༊᜕Б
މfৰϤʘ̮dਖ਼л ج ͵ස০࿁ᖹۜਖ਼лணϞމ ̈ɹͦٙʘ੶Փબᛆԫ͟€ਖ਼лج ୋ 90 ૢ
˸ɨਞ๫f
8 Busse/Keukenschrijver, Patentgesetz, 7. Aufl., Berlin, 2013, ² 1 Rdnr. 110.
9 Ge Shu, The Japanese Patent Examination and Training System (final report), WIPO Funds-In-
Trust/Japan Research Fellowship, Mar. 21, 2001–Sep. 20, 2001, at 10-11 (available at http://
, last visited 15 October
2016).
10 ਷ყʮߒ࿁׵ୋɧ˰ޢ ਷࢕݊щ ڭ ᚐᖹۜ೯׼d͵મ՟༰ މᄱ࢙࿒ܓf TRIPS ՘֛ୋ 65 ૢ
ୋ 4 ධʿୋ 66 ૢୋ 1 ධ׼˖஝֛dක೯ʕ਷࢕ึࡰ€developing country MembersʿЭܓ
ක೯਷࢕ึࡰ€least-developed country MembersЇ 2006 ϋ֐ცו Ⴉᖹۜਖ਼лᛆf2003 ϋ
ʿ 2015 ϋ WTO ึࡰʱйЪϓӔᙄdਗ਼Э ೯ܓ ਷࢕ึࡰʘ౧ۃ ່ਕַ࢝Ї 2016 ϋʿ 2033
ϋfਞԈ IP/C/73 (6 November 2015, available at
pharmpatent_e.htm, last visited 15 October 2016).
ᗫdʔሞ݊lz਷אج਷ყʮ ߒdѩ̙Ԉਖ਼лجਗ਼ᖹۜ೯׼ॶɝڭᚐʘतࣿ׌ 7f
一、專利適格性
০࿁ᖹۜ೯׼ʘਖ਼лቇࣸ׌dৰə ߕ ਷੽ɓක֐ٙ 1790 ϋਖ਼л ج€The
Patent Act of 1790у וႩ̮dεᅰ਷࢕ѩਿ׵ʮ΍ሊ͛ϽඎϾщႩᖹۜ೯׼ʘਖ਼
лڭᚐd׵ૉڐe ޟϾ݊ɖ´ϋ˾˸ ܝd֐וႩʷኪ يሯʿᖹۜʘਖ਼лቇࣸ׌d
ίϤʘ ۃdසՉႡி˙אجႡ೻ঐᐏ ࡘ˙ج ਖ਼лfԷνjᅃ਷ί 1967 ϋਖ਼л ج
ࡌ ͍ۃd׼ࠈභ࠮ۜeෘλۜeᔼᖹʿʷኪ೻ҏה Ⴁிʘيሯʔʚਖ਼л 8i˚͉
׵ 1975 ϋ֐ਞ๫ߕ਷ਖ਼л جˏආ يሯਖ਼лՓܓ€substance patent system9f
Νᅵٙd੽ਖ਼лجٙ೯࢝ዝ̦Ը޶dҢ਷ૉڐ֐וႩᖹۜ೯׼ʘਖ਼лቇࣸ׌f
׸Ԋʘd1944 ϋ਷͏ִ݁уʊʮ̺ਖ਼лجૢ˖dઓٜЇ 1979 ϋࡌ͍ʮ̺ʘਖ਼л
جୋ 4 ૢୋ 1 ʿ 3 ಛʥ׼˖஝֛dʷኪۜeᔼᖹۜʿՉሜΥۜʔʚਖ਼лdසᖹۜ
Υϓ˙ ج€synthesizing אՉ˼Ⴁ೻dঐᐏࡘ ˙ج ਖ਼лᛆf፰Ї 1986 ϋਖ਼л ج
ࡌ ͍֐мৰ౧ۃૢ˖dٵ֛˸˜ي™މᅺٙʘᖹۜ೯׼Ոਖ਼лቇࣸ׌ 10f
二、延續性藥品發明之專利保護
ᗫ׵ᖹۜ೯׼ʘਖ਼лቇࣸ׌dͦۃ ί ߕ ᆄ˚ᒵeҢ਷ʿՉ˼ʊක೯਷࢕
ʊೌဲ່fΪϤdҢ਷০࿁ᖹۜʘي ٙ೯׼dආɓӉୌΥ̙ਖ਼л׌ࠅ ΁€ਖ਼л
جୋ 22 ૢਞ๫d˲Չ͡ሗୌΥ̂ʱ౧ᚣʿኽ˸ྼତʘࠅ Ӌ€ਖ਼лجୋ 26 ૢ
ୋ 1 ධਞ๫dᏐ̙ᐏࡘਖ਼лfྼਕɪʔ˶˸ᖹۜʷኪഐ࿴€chemical structure